Basic Information
Lenvima
Regulatory Information
EMEA/H/C/003727
May 28, 2015
March 26, 2015
26
September 17, 2024
Company Information
Germany
Edmund-Rumpler-Straße 3 60549 Frankfurt am Main
Eisai GmbH
Drug Classification
Active Substances Detail
lenvatinib mesilate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Overview Summary
Lenvima is a cancer medicine used to treat adults with: - differentiated thyroid carcinoma, a type of cancer originating from the follicular cells of the thyroid gland. Lenvima is used on its own when the cancer has progressed or spread locally or to other parts of the body, and does not respond to treatment with radioactive iodine; - hepatocellular carcinoma (a type of liver cancer). It is used on its own in patients who did not previously receive a cancer medicine by mouth or by injection and whose cancer is advanced or cannot be removed by surgery; - endometrial carcinoma (cancer of the lining of the womb). It is used together with another cancer medicine, pembrolizumab, in patients whose disease is advanced or has come back after previous treatment involving platinum-based cancer medicines, when surgery or radiation to cure the cancer is not possible. Lenvima contains the active substance lenvatinib.